A phase 2 trial is investigating MTX-001, an injectable regenerative therapy, for patients with noninfected venous leg ulcers.

A New Drug Application for the investigational oral selective estrogen receptor degrader giredestrant has received Priority ...

Increased T-cell receptor clonality and novel clonotypes seen with intismeran plus pembrolizumab versus pembrolizumab alone.

Clinically meaningful improvements seen in overall, progression-free survival for those with RAS G12 mutation, overall population.

Zaynich is a combination of cefepime, a cephalosporin antibacterial, and zidebactam, a beta-lactamase inhibitor and non-beta-lactam antibacterial.

A total of 10,225 patients with stage I to III cancer who initiated GLP-1 RA therapy after diagnosis were identified for the trial. HealthDay News — Across multiple solid tumors, glucagon-like peptide ...

Backed by phase 3 INHALE-1 data, the expanded indication provides a noninvasive, needle-free mealtime insulin alternative for children and adolescents.

While California has some of the strictest vaccine laws in the country, conservative Shasta County’s approach during the COVID pandemic stood in stark contrast with the state’s guidance.

The court cited threats to Kenyan lives and barred entrance to the country to anyone from Ebola-affected regions ...

The combination regimen significantly improved progression-free survival and objective response rates in patients who were intolerant to or failed prior imatinib therapy ...

The 3-month extension follows a major amendment to the NDA for the intrathecal cyclodextrin-based therapy, which has shown a 71% reduction in mortality risk in clinical trials.

Backed by the phase 2b/3 EPICS-III trial, saroglitazar demonstrated a significant 56.7% biochemical response rate compared with 9.8% for placebo, while showing favorable safety data.